Suppr超能文献

Sp1样序列介导p73和顺铂对人半胱天冬酶-3启动子的激活作用。

Sp1-like sequences mediate human caspase-3 promoter activation by p73 and cisplatin.

作者信息

Sudhakar Cherukuri, Jain Nishant, Swarup Ghanshyam

机构信息

Centre for Cellular and Molecular Biology, Hyderabad, India.

出版信息

FEBS J. 2008 May;275(9):2200-13. doi: 10.1111/j.1742-4658.2008.06373.x. Epub 2008 Apr 1.

Abstract

Caspase-3 is a cysteine protease that plays a central role in the execution of apoptosis induced by a wide variety of stimuli. However, little is known about the mechanisms involved in the regulation of caspase-3 gene transcription. This study was carried out to characterize the human caspase-3 promoter and to understand the mechanisms involved in the induction of caspase-3 gene expression in response to the anticancer drug cisplatin and p73. Caspase-3 gene expression was induced by treatment of cells with cisplatin, which also induced p73 protein in HeLa and K562 cells. The human caspase-3 promoter was cloned and characterized. p73beta strongly activated the caspase-3 promoter, whereas p73alpha showed less activation. Cisplatin treatment increased caspase-3 promoter activity. Basal and cisplatin-induced promoter activity was inhibited by the p73 inhibitor p73DD. Deletion analysis defined a minimal promoter of 120 base pairs, which showed good basal and p73beta-induced activity. The examination of the minimal promoter sequence showed several putative Sp1 sites, but no p53/p73 site. The caspase-3 promoter was activated by Sp1 in Sp1-deficient Drosophila SL-2 cells. Sp1-induced promoter activity was further enhanced by p73beta in SL-2 cells. Mutation of Sp1 sites in the minimal promoter resulted in a loss of basal and p73-induced promoter activity. These results show that caspase-3 gene transcription is induced by cisplatin, which is mediated partly by p73. We have identified p73 and Sp1 as activators of the caspase-3 promoter. Sp1-like sequences in the minimal promoter not only sustain basal promoter activity, but also mediate p73-induced activation of the promoter.

摘要

半胱天冬酶-3是一种半胱氨酸蛋白酶,在多种刺激诱导的细胞凋亡执行过程中发挥核心作用。然而,关于参与调控半胱天冬酶-3基因转录的机制却知之甚少。本研究旨在表征人半胱天冬酶-3启动子,并了解在抗癌药物顺铂和p73作用下诱导半胱天冬酶-3基因表达的机制。用顺铂处理细胞可诱导半胱天冬酶-3基因表达,顺铂在HeLa和K562细胞中还可诱导p73蛋白表达。克隆并表征了人半胱天冬酶-3启动子。p73β强烈激活半胱天冬酶-3启动子,而p73α的激活作用较弱。顺铂处理可增加半胱天冬酶-3启动子活性。p73抑制剂p73DD可抑制基础和顺铂诱导的启动子活性。缺失分析确定了一个120个碱基对的最小启动子,其具有良好的基础活性和p73β诱导活性。对最小启动子序列的检查显示有几个假定的Sp1位点,但没有p53/p七3位点。在缺乏Sp1的果蝇SL-2细胞中,Sp1可激活半胱天冬酶-3启动子。在SL-2细胞中,p73β可进一步增强Sp1诱导的启动子活性。最小启动子中Sp1位点的突变导致基础和p73诱导的启动子活性丧失。这些结果表明,顺铂可诱导半胱天冬酶-3基因转录,部分由p73介导。我们已确定p73和Sp1为半胱天冬酶-3启动子的激活剂。最小启动子中的Sp1样序列不仅维持基础启动子活性,还介导p七3诱导的启动子激活。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验